ATE348104T1 - Azyklische linker enthaltende oligonukleotide und deren verwendungen - Google Patents

Azyklische linker enthaltende oligonukleotide und deren verwendungen

Info

Publication number: ATE348104T1
Authority: AT; Austria
Prior art keywords: nucleic acid; target nucleic; prevention; function; oligonucleotides containing
Prior art date: 2001-10-29

Application number

AT02769804T

Other languages

English (en)

Inventor

Masad J Damha

Ekaterina Viazovkina

Maria M Mangos

Michael A Parniak

Kyung-Lyum Min

Original Assignee

Univ Mcgill

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-29

Filing date

2002-10-29

Publication date

2007-01-15

2002-10-29 Application filed by Univ Mcgill filed Critical Univ Mcgill

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE348104T1 publication Critical patent/ATE348104T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 4
150000007523 nucleic acids Chemical class 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 4
230000002265 prevention Effects 0.000 abstract 3
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
238000004458 analytical method Methods 0.000 abstract 1
239000000074 antisense oligonucleotide Substances 0.000 abstract 1
238000012230 antisense oligonucleotides Methods 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
238000010839 reverse transcription Methods 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

AT02769804T 2001-10-29 2002-10-29 Azyklische linker enthaltende oligonukleotide und deren verwendungen ATE348104T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33071901P	2001-10-29	2001-10-29

Publications (1)

Publication Number	Publication Date
ATE348104T1 true ATE348104T1 (de)	2007-01-15

Family

ID=23291016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02769804T ATE348104T1 (de)	2001-10-29	2002-10-29	Azyklische linker enthaltende oligonukleotide und deren verwendungen

Country Status (9)

Country	Link
US (1)	US20050233455A1 (de)
EP (1)	EP1440079B1 (de)
JP (1)	JP2005508634A (de)
AT (1)	ATE348104T1 (de)
CA (1)	CA2465129A1 (de)
DE (1)	DE60216798T2 (de)
MX (1)	MXPA04004056A (de)
NZ (1)	NZ532610A (de)
WO (1)	WO2003037909A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7563618B2 (en)	2001-03-23	2009-07-21	Geron Corporation	Oligonucleotide conjugates
MX2007005083A (es)	2004-10-29	2007-10-03	Topigen Pharmaceuticals Inc	Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
US8354227B2 (en) *	2006-02-03	2013-01-15	Columbia University In The City Of New York	Binary deoxyribozyme probes for nucleic acid analysis
AU2007252192B2 (en)	2006-05-19	2013-10-17	Topigen Pharmaceuticals Inc.	Oligonucleotides affecting expression of phosphodiesterases
EP3034083B1 (de) *	2006-09-21	2020-12-09	University of Rochester	Antisense-oligonukleotide zur behandlung von myotoner dystrophie
BRPI0811170B8 (pt) *	2007-05-22	2021-05-25	Arcturus Therapeutics Inc	oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
CN102099474B (zh)	2008-05-15	2014-05-28	托皮根药品公司	用于治疗炎症和赘生性细胞增殖的寡核苷酸
JP5816556B2 (ja)	2008-12-03	2015-11-18	アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	治療剤のためのｕｎａオリゴマー構造
US20110262989A1 (en) *	2010-04-21	2011-10-27	Nanomr, Inc.	Isolating a target analyte from a body fluid
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2012027206A1 (en) *	2010-08-24	2012-03-01	Merck Sharp & Dohme Corp.	SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
EA033653B1 (ru) *	2011-09-05	2019-11-13	Stichting Katholieke Univ	Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
JP6129844B2 (ja)	2011-09-14	2017-05-17	ラナセラピューティクスインコーポレイテッド	多量体オリゴヌクレオチド化合物
WO2013103146A1 (ja) *	2012-01-07	2013-07-11	株式会社ボナック	アミノ酸骨格を有する一本鎖核酸分子
JP2015523853A (ja)	2012-05-16	2015-08-20	ラナセラピューティクスインコーポレイテッド	Ａｔｐ２ａ２発現を調節するための組成物及び方法
SG11201407486PA (en)	2012-05-16	2014-12-30	Rana Therapeutics Inc	Compositions and methods for modulating utrn expression
EA201492121A1 (ru)	2012-05-16	2015-10-30	Рана Терапьютикс, Инк.	Композиции и способы для модулирования экспрессии семейства генов гемоглобина
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
AU2013262709A1 (en)	2012-05-16	2015-01-22	Rana Therapeutics, Inc.	Compositions and methods for modulating MECP2 expression
KR20150030205A (ko)	2012-05-16	2015-03-19	라나 테라퓨틱스, 인크.	Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
CN109810977A (zh)	2012-05-26	2019-05-28	株式会社博纳克	具有递送功能的基因表达调控用单链核酸分子
CA2884608C (en)	2012-09-14	2025-05-20	Translate Bio Ma, Inc.	MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
JP2016534035A (ja)	2013-10-04	2016-11-04	ラナセラピューティクスインコーポレイテッド	筋萎縮性側索硬化症を治療するための組成物及び方法
US10612020B2 (en)	2013-12-26	2020-04-07	Tokyo Medical University	Artificial mimic miRNA for controlling gene expression, and use of same
WO2015099187A1 (ja)	2013-12-27	2015-07-02	株式会社ボナック	遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
AU2015236215B2 (en)	2014-03-25	2020-03-19	Arcturus Therapeutics, Inc.	UNA oligomers having reduced off-target effects in gene silencing
JP6771387B2 (ja)	2014-03-25	2020-10-21	アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
US9856475B2 (en)	2014-03-25	2018-01-02	Arcturus Therapeutics, Inc.	Formulations for treating amyloidosis
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
US11027023B2 (en)	2014-12-27	2021-06-08	Bonac Corporation	Natural type miRNA for controlling gene expression, and use of same
GB201503408D0 (en)	2015-02-27	2015-04-15	Proqr Therapeutics N V	Oligonucleotides
US11142769B2 (en)	2015-03-27	2021-10-12	Bonac Corporation	Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
EP3277289A4 (de)	2015-04-01	2018-12-05	Arcturus Therapeutics, Inc.	Therapeutische una-oligomere und verwendungen davon
US10851371B2 (en)	2015-04-10	2020-12-01	Ionis Pharmaceuticals, Inc.	Modulation of SMN expression
WO2017015671A1 (en)	2015-07-23	2017-01-26	Arcturus Therapeutics, Inc.	Compositions for treating amyloidosis
WO2017218884A1 (en) *	2016-06-16	2017-12-21	Ionis Pharmaceuticals, Inc.	Combinations for the modulation of smn expression
US11110180B2 (en)	2017-10-04	2021-09-07	Avidity Biosciences Inc.	Nucleic acid-polypeptide compositions and uses thereof
AU2019408408A1 (en) *	2018-12-21	2021-06-03	Valerio Therapeutics	New conjugated nucleic acid molecules and their uses
US12006499B2 (en) *	2019-06-06	2024-06-11	Avidity Biosciences, Inc.	Una amidites and uses thereof
CA3142283A1 (en)	2019-06-06	2020-12-10	Avidity Biosciences, Inc.	Nucleic acid-polypeptide compositions and uses thereof
PH12022552258A1 (en)	2020-02-28	2023-11-20	Ionis Pharmaceuticals Inc	Compounds and methods for modulating smn2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5399676A (en) *	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5674683A (en) *	1995-03-21	1997-10-07	Research Corporation Technologies, Inc.	Stem-loop and circular oligonucleotides and method of using
DE69637256T2 (de) *	1996-01-16	2008-06-19	Sirna Therapeutics, Inc., Boulder	Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
US6468983B2 (en) *	1997-04-21	2002-10-22	The Cleveland Clinic Foundation	RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
WO1999054459A2 (en) *	1998-04-20	1999-10-28	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
EP0978561A1 (de) *	1998-08-07	2000-02-09	Hoechst Marion Roussel Deutschland GmbH	Antisense Oligonukleotide zur Hemmung von VEGF-Expression

2002
- 2002-10-29 DE DE60216798T patent/DE60216798T2/de not_active Expired - Lifetime
- 2002-10-29 CA CA002465129A patent/CA2465129A1/en not_active Abandoned
- 2002-10-29 AT AT02769804T patent/ATE348104T1/de not_active IP Right Cessation
- 2002-10-29 EP EP02769804A patent/EP1440079B1/de not_active Expired - Lifetime
- 2002-10-29 MX MXPA04004056A patent/MXPA04004056A/es unknown
- 2002-10-29 NZ NZ532610A patent/NZ532610A/en unknown
- 2002-10-29 WO PCT/CA2002/001628 patent/WO2003037909A1/en not_active Ceased
- 2002-10-29 US US10/494,141 patent/US20050233455A1/en not_active Abandoned
- 2002-10-29 JP JP2003540190A patent/JP2005508634A/ja active Pending

Also Published As

Publication number	Publication date
CA2465129A1 (en)	2003-05-08
MXPA04004056A (es)	2004-09-10
DE60216798D1 (de)	2007-01-25
WO2003037909A1 (en)	2003-05-08
NZ532610A (en)	2008-03-28
EP1440079B1 (de)	2006-12-13
US20050233455A1 (en)	2005-10-20
EP1440079A1 (de)	2004-07-28
JP2005508634A (ja)	2005-04-07
DE60216798T2 (de)	2007-10-18

Legal Events

Date	Code	Title	Description
2007-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60216798D1 (de)	2007-01-25	Azyklische linker enthaltende oligonukleotide und deren verwendungen
DK1470144T3 (da)	2009-04-06	Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
WO2002052031A3 (en)	2002-09-12	Nucleic acid amplification
ES2118593T3 (es)	1998-09-16	Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
CY1111645T1 (el)	2015-10-07	Συνθετικα ολιγονουκλεοτιδια διπλης ελικας για την στοχευμενη αναστολη της γονιδιακης εκφρασης
ATE154029T1 (de)	1997-06-15	7-deazapurin modifizierte oligonukleotide
WO2007062160A8 (en)	2008-02-14	Methods and compositions for sequencing a nucleic acid
PT731835E (pt)	2002-11-29	Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
WO2005047477A3 (en)	2009-04-02	Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2006002038A3 (en)	2008-07-17	Immunostimulatory oligonucleotide multimers
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
ATE506372T1 (de)	2011-05-15	Verfahren zur herstellung von nukleosidderivate
AR030961A1 (es)	2003-09-03	Secuencias de nucleotidos que intervienen en la fertilidad masculina en plantas y metodo de uso de las mismas
PT1268471E (pt)	2004-03-31	Derivados n-heterociclicos como inibidores de nos
PA8552501A1 (es)	2003-06-30	1-alquil o 1-cicloalquil-triazolo[4,3-a]quinazolin-5-onas como inhibidoras de fosfodiesterasa
WO2015009678A2 (en)	2015-01-22	Specific targeting of rna expanded repeat sequences
WO2003101394A3 (en)	2004-11-11	Defensins: use as antiviral agents
DK1175489T3 (da)	2006-10-02	Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
CA2506797A1 (en)	2004-06-10	Detectable labeled nucleoside analogs and methods of use thereof
Suydam et al.	2008	Fluorine substituted adenosines as probes of nucleobase protonation in functional RNAs
EP1480992A4 (de)	2007-02-07	Telomeraseinterferenz
ATE532509T1 (de)	2011-11-15	Mittel zur hemmung des eintritts des hiv-virus
WO2001040521A3 (en)	2002-05-16	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
Maier et al.	2002	Postsynthetic guanidinylation of primary amino groups in the minor and major grooves of oligonucleotides
ATE332967T1 (de)	2006-08-15	Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit